自民國79年12月至80年12月共計有54位攝護腺肥大患者接受高溫治療，經由尿道內置放導管將攝護腺加熱至攝氏44.5度並維持三小時。結果在20位長期留置尿管的病患中有12位（60%）可以不用再賴尿管。第一、三、六及十二個月追蹤調查時分別有42.5%、75.8%、60.9%及75%的患者在主觀症狀上有顯著改善。然而最大尿流速度比治療前進步超過50%者僅有21.4%、27.6%、17.4%和16.7%；至於餘尿量有顯著減少者則分別只有16.7%、20.7%、13%及8.3%。在治療過程中病人有尿道灼痛（63%）及膀胱不自主收縮（37%）等不適感；治療後則有小便疼痛（79%）、血尿（51%）、急性尿渚留（15%）等副作用。整體而言攝護腺高溫治療對於手術高危險群患者不失為一安全而有效的支持療法。

From December 1990 to December 1991, a total of 54 patients with benign prostatic hyperplasia were treated by a transurethral hyperthermic device using 44.5℃ in a single session of three hours duration. Twelve of 20 patients (60%) with indwelling urethral catheter became catheter free after hyperthermic treatment. There were 48.5%, 75.8%, 60.9% and 76.2% of the patients who showed more than 50% decrease in subjective symptom scores at 1-, 3-, 6- and 12-month follow-up, respectively. However, only 21.2%, 27.6%, 17.4% and 14.3% of the patients had more than 50% increase of peak uroflow rate; 18.1%, 20.7% 13%, and 9.5% of the patients showed more than 50% decrease of residual urine at each follow-up visit. During treatment, some had urtethral pain (63%) or bladder spasm (37%). In the following days, 42 patients (79%) had dysuria, 27 cases (37%). In the following days, 42 patients (79%) had dysuria, 27 cases (51%) had microscopic to gross hematuria and 8 patients (15%) suffered from acute urinary reatention. All symptoms were tolerable and self-limiting. Thus, based on our limited experience transurethral hyperthermic treatment might be considered as an alternative for patients with BPH who otherwise run high operational risk.